pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma
Ningbo Cancer Hospital
Ningbo Cancer Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Muscle-invasive bladder cancer, Unresectable intrahepatic cholangiocarcinoma, Head and neck squamous cell carci
Company details
- Status
- Public
- HQ
- CN
- Programs
- 120
- Drugs
- 183
- Patents
- 0
Tevimbra 100 mg concentrate for solution for infusion
Phase 2 · small molecule · Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.
Tevimbra 100 mg concentrate for solution for infusion for Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy. is a Phase 2 program (small_molecule) at Ningbo Cancer Hospital with 1 ClinicalTrials.gov record(s).
Internal code UC-GIG-2003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ningbo Cancer Hospital
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.
- Status
- active
- Trials
- 1